IMA Wealth Inc. Reduces Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

IMA Wealth Inc. trimmed its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.7% during the 4th quarter, Holdings Channel reports. The firm owned 2,967 shares of the biopharmaceutical company’s stock after selling 320 shares during the period. Regeneron Pharmaceuticals comprises 1.3% of IMA Wealth Inc.’s investment portfolio, making the stock its 27th biggest position. IMA Wealth Inc.’s holdings in Regeneron Pharmaceuticals were worth $2,606,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. FMR LLC raised its position in shares of Regeneron Pharmaceuticals by 7.3% during the 3rd quarter. FMR LLC now owns 9,840,892 shares of the biopharmaceutical company’s stock valued at $8,098,661,000 after purchasing an additional 669,517 shares during the period. Northern Trust Corp increased its holdings in Regeneron Pharmaceuticals by 3.3% in the 3rd quarter. Northern Trust Corp now owns 1,067,210 shares of the biopharmaceutical company’s stock valued at $878,271,000 after acquiring an additional 34,326 shares during the last quarter. Morgan Stanley increased its holdings in Regeneron Pharmaceuticals by 2.7% in the 3rd quarter. Morgan Stanley now owns 970,957 shares of the biopharmaceutical company’s stock valued at $799,061,000 after acquiring an additional 25,792 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in Regeneron Pharmaceuticals by 0.3% in the 3rd quarter. Bank of New York Mellon Corp now owns 967,414 shares of the biopharmaceutical company’s stock valued at $796,142,000 after acquiring an additional 2,666 shares during the last quarter. Finally, American Century Companies Inc. increased its holdings in Regeneron Pharmaceuticals by 3.4% in the 3rd quarter. American Century Companies Inc. now owns 916,718 shares of the biopharmaceutical company’s stock valued at $754,422,000 after acquiring an additional 30,050 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Trading Down 0.8 %

REGN stock traded down $7.48 during mid-day trading on Friday, reaching $883.20. The company had a trading volume of 505,652 shares, compared to its average volume of 431,865. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.69 and a quick ratio of 4.94. The company has a market capitalization of $96.94 billion, a PE ratio of 25.42, a price-to-earnings-growth ratio of 2.56 and a beta of 0.11. The firm has a 50 day moving average of $948.00 and a 200 day moving average of $893.63. Regeneron Pharmaceuticals, Inc. has a 12 month low of $684.80 and a 12 month high of $998.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, topping analysts’ consensus estimates of $10.73 by $1.13. The business had revenue of $3.43 billion for the quarter, compared to the consensus estimate of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The company’s revenue for the quarter was up .6% compared to the same quarter last year. During the same period in the prior year, the firm earned $10.96 EPS. On average, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 38.8 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,000 shares of the company’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $934.71, for a total value of $934,710.00. Following the transaction, the executive vice president now directly owns 13,789 shares in the company, valued at approximately $12,888,716.19. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $982.05, for a total transaction of $98,205.00. Following the transaction, the director now directly owns 18,282 shares in the company, valued at $17,953,838.10. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Marion Mccourt sold 1,000 shares of the stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $934.71, for a total transaction of $934,710.00. Following the transaction, the executive vice president now owns 13,789 shares in the company, valued at $12,888,716.19. The disclosure for this sale can be found here. Insiders have sold 11,022 shares of company stock worth $10,552,991 in the last three months. Corporate insiders own 8.83% of the company’s stock.

Analyst Ratings Changes

REGN has been the topic of a number of research reports. UBS Group lifted their price target on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a report on Wednesday, April 17th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $925.00 price target on shares of Regeneron Pharmaceuticals in a report on Monday, April 15th. BMO Capital Markets lifted their price target on shares of Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an “outperform” rating in a report on Monday, February 5th. Bank of America boosted their target price on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a report on Friday, April 12th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $1,189.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 9th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $977.77.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.